EcoDrugPlus

Phospholipase A2 Group Vii

Ensembl ID : ENSELUG00000010326
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSELUG00000001749
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen

Ensembl ID : ENSELUG00000021987
Gene Symbol: PLG
3 Cross references
261 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSELUG00000009537
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSELUG00000032181
Gene Symbol: PTAFR
1 Cross references
222 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSELUG00000028539
Gene Symbol: PTAFR
1 Cross references
222 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSELUG00000026852
Gene Symbol: PTAFR
1 Cross references
222 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta

Ensembl ID : ENSELUG00000024474
Gene Symbol: LOC105030015
3 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSELUG00000016639
Gene Symbol: LOC105025839
3 Cross references
199 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSELUG00000016673
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSELUG00000009850
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSELUG00000017336
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).